Jeff Jonas, an analyst at Gabelli & Co., says he recommends shares of Bristol-Myers Squibb and Watson Pharmaceuticals. Jonas talks with Bloomberg's Ken Prewitt, Tom Keene and Sara Eisen on Bloomberg Radio's "Bloomberg Surveillance."
Johnson & Johnson , the world’s second-biggest seller of health products, increased its annual earnings forecast after quarterly profit beat estimates on drug sales and a weak dollar. The shares rose the most since 2008.
U.S. companies such as AT&T Inc. and Johnson & Johnson are paying less tax than before the recession even as profits have rebounded, buoyed by breaks and expansion in overseas markets, where the tax burden is lower.